Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gene Expression Assays and 68 Ga-Affibody HER-2 Imaging PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Chinese Patients With HER2 Positive Breast Cancer

Next Previous
Trial Profile

Gene Expression Assays and 68 Ga-Affibody HER-2 Imaging PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Chinese Patients With HER2 Positive Breast Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PHC-BC

Most Recent Events

  • 30 Apr 2020 Planned End Date changed from 30 Jan 2030 to 30 Apr 2030.
  • 30 Apr 2020 Planned primary completion date changed from 30 Jan 2025 to 30 Apr 2025.
  • 30 Apr 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top